Federal Decree-Law No. 21 of 2025 on Veterinary Medical Products and Veterinary Pharmaceutical Establishments introduces the UAE's first consolidated federal regime for the entire life cycle of veterinary medicines — from development and registration through manufacturing, import, distribution, sale, use, disposal and advertising. Licensing and oversight are shared between the Emirates Drug Establishment (EDE) and the Ministry of Climate Change and Environment (MOCCAE), and every operator in the chain must hold the correct authorisation.
Who should read this
Manufacturers and contract manufacturers of veterinary medicines; importers, exporters and distributors; veterinary pharmacies, warehouses and stores; and the marketing, consulting and laboratory offices that support them. In-house counsel, regulatory-affairs teams and food-security operators with animal-health supply chains should also review their licensing position before the transitional window closes.
Directly affected
Key facts
- Instrument: Federal Decree-Law No. (21) of 2025 on Veterinary Medical Products and Veterinary Pharmaceutical Establishments.
- Level: Federal — applies across all seven Emirates, including free zones, subject to the competent local authority's approvals.
- Issued: 2025, announced in December 2025; it enters into force on publication in the Official Gazette (the enacted Arabic text governs the exact date).
- Regulators: Emirates Drug Establishment (EDE) and the Ministry of Climate Change and Environment (MOCCAE), each within its jurisdiction and after local-authority approval.
- Scope of products: veterinary preparations (including biological products and injectable supplements), raw materials, supplementary products, veterinary medical devices, GMOs for veterinary use, and controlled, semi-controlled and precursor substances.
- Regulated activities: development, manufacturing, registration, pricing, import, export, distribution, possession, sale, display, re-marketing, use, safe disposal, advertising and promotion.
- Transitional relief: a compliance window of up to one year from entry into force for existing establishments and products, extendable by Cabinet decision.
Executive summary
The Decree-Law pulls veterinary medicines into a dedicated federal framework rather than treating them as an adjunct to human-pharmaceutical or general agricultural rules. Two authorities now hold the pen: the Emirates Drug Establishment sets product and establishment standards on the medicines side, while MOCCAE covers the animal-health and environmental dimension, each acting after the competent local authority's approvals. For operators, the practical shift is that nearly every commercial act touching a veterinary medical product — registering it, pricing it, importing it, warehousing it, selling it, advertising it or disposing of it — now requires a licence or authorisation traceable to this regime. A one-year transitional window softens the change, but it is a deadline, not an indefinite grace period.
What changed
Previously the sector was governed by a patchwork of general pharmaceutical, agricultural and local rules with no single federal instrument dedicated to veterinary medicines. The Decree-Law consolidates that patchwork and adds several concrete features:
- A unified product and establishment regime. One law now defines what counts as a veterinary medical product and what counts as a veterinary pharmaceutical establishment — pharmacies, warehouses and stores, manufacturing plants, contract manufacturers, marketing offices, consulting offices and laboratories — and subjects each to licensing.
- Split federal oversight. The EDE and MOCCAE share competence, so an operator's licensing pathway depends on the activity and product type, and local-authority approvals remain a prerequisite.
- A fast-track authorisation route. For the first time the sector has a simplified marketing-authorisation pathway for innovative products of high therapeutic value, aligned with quality, safety and efficacy standards and international agreements.
- End-to-end control of the supply chain. Import, export, distribution, possession, display, re-marketing, safe disposal, advertising and promotion are all expressly regulated, closing gaps that previously sat between agencies.
Practical implications
Existing operators should not assume current licences carry over. The transitional window is the period in which to map every product and activity against the new authorisation categories, identify which regulator (EDE or MOCCAE) holds competence for each, and confirm the local-authority approvals that sit alongside the federal licence. Manufacturers and contract manufacturers should expect good-manufacturing-practice expectations to be applied and evidenced. Importers and distributors should review supply contracts, incoterms and product-recall responsibilities against the new import, distribution and disposal obligations. Marketing and consulting offices should audit promotional materials, because advertising and promotion of veterinary products are now expressly within scope. Businesses developing novel products should assess whether they qualify for the fast-track route, which can materially shorten time to market. Because penalties and enforcement mechanics are set by the enacted text and its implementing resolutions, operators should treat compliance planning as time-sensitive rather than deferring it to the end of the window.
Action points
- Build a register of every veterinary product and activity your business handles, and map each to the new licensing and authorisation categories.
- Confirm which regulator — EDE or MOCCAE — has competence for each product and activity, and identify the required competent-local-authority approvals.
- Diarise the transitional deadline (up to one year from entry into force) and start the establishment re-licensing and product-registration process early.
- Review manufacturing, import, distribution and disposal procedures against good-practice expectations, and update supply and contract-manufacturing agreements accordingly.
- Audit advertising and promotional materials for veterinary products and confirm they meet the new requirements.
- Assess whether any innovative products qualify for the fast-track marketing-authorisation route.
Enforcement and transitional relevance
The Decree-Law's transitional window is finite and extendable only by Cabinet decision — it is not an open-ended exemption. Operating an unlicensed establishment, distributing unregistered products, or advertising outside the new rules after the window closes exposes a business to administrative and penal consequences set by the enacted text and its implementing resolutions (including MOCCAE's technical requirements for veterinary establishments). Where a specific sanction, fee or deadline matters to a decision, verify it against the enacted Arabic text and the relevant implementing resolution, which prevail over any English summary.
Directly affected: veterinary medical product manufacturers and contract manufacturers, importers, exporters and distributors, veterinary pharmacies, warehouses and stores, and marketing, consulting and laboratory offices.
Sources and authorities
Federal Decree-Law No. (21) of 2025 on Veterinary Medical Products and Veterinary Pharmaceutical Establishments — official text via the UAE Legislation Portal.
https://uaelegislation.gov.ae/en/legislations/3942
Implementing detail: Ministerial Resolution No. 27 of 2026 (MOCCAE) on the health and technical requirements for veterinary establishments. This is a new federal instrument consolidating and superseding the prior patchwork of general pharmaceutical and agricultural rules for veterinary medicines; it does not amend a single named predecessor law. The enacted Arabic text and its implementing resolutions prevail.
Original-source date: 2025 · Captured: 2026-05-18T18:15+00:00Z
Instrument details
Full title: Federal Decree-Law No. (21) of 2025 on Veterinary Medical Products and Veterinary Pharmaceutical Establishments.
Type & level: Federal Decree-Law, applicable throughout the UAE.
Regulators: Emirates Drug Establishment (EDE) and the Ministry of Climate Change and Environment (MOCCAE), each within its jurisdiction and after the competent local authority's approvals.
Covered establishments: veterinary pharmacies; veterinary medical warehouses and stores; manufacturing plants; contract-manufacturing companies; marketing offices; pharmaceutical consulting offices; and pharmaceutical laboratories.
Transitional period: up to one year from entry into force for existing operators and products to comply, extendable by Cabinet decision.
Language: the enacted Arabic text is authoritative. This note is an English-language summary prepared from official announcements and the Legislation Portal listing; it is not a verbatim translation.
Based on Federal Decree-Law No. (21) of 2025 on Veterinary Medical Products and Veterinary Pharmaceutical Establishments and cross-checked against leading practitioner analyses. General information only — it does not constitute legal advice, and the enacted Arabic text prevails. For advice on a specific matter, please contact us. Last updated: 2 July 2026.